(IOVA) Iovance Biotherapeutics - Overview
Stock: Amtagvi, Proleukin, Lifileucel
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 97.1% |
| Relative Tail Risk | -15.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.26 |
| Alpha | -79.68 |
| Character TTM | |
|---|---|
| Beta | 1.478 |
| Beta Downside | 0.760 |
| Drawdowns 3y | |
|---|---|
| Max DD | 90.50% |
| CAGR/Max DD | -0.33 |
Description: IOVA Iovance Biotherapeutics January 26, 2026
Iovance Biotherapeutics (NASDAQ: IOVA) is a commercial-stage biotech that focuses on autologous tumor-infiltrating lymphocyte (TIL) therapies for metastatic melanoma and other solid tumors in the United States. Its flagship product, Amtagvi, is an FDA-approved TIL therapy for unresectable or metastatic melanoma, and the company also markets Proleukin (IL-2) for melanoma and metastatic renal cell carcinoma.
Beyond the approved indication, Iovance is advancing a pipeline of TIL-based candidates: lifileucel (currently in Phase 2/3 trials for melanoma, cervical cancer, NSCLC, endometrial cancer, and head-and-neck squamous cell carcinoma), IOV-2001 for chronic lymphocytic leukemia/small lymphocytic lymphoma, IOV-4001 targeting melanoma and NSCLC, and IOV-3001, an antibody-cytokine fusion designed to augment TIL regimens. As of Q4 2025, lifileucel reported an objective response rate of 38 % in the pivotal melanoma cohort, meeting its primary endpoint.
Financially, Iovance reported FY 2025 revenue of $62 million, driven primarily by Amtagvi sales, and ended the year with $380 million in cash, cash equivalents, and short-term investments-sufficient to fund operations into mid-2027 at the current burn rate of roughly $85 million per year. However, R&D expense grew 27 % YoY to $115 million, reflecting the expanding trial portfolio, which adds execution risk if later-stage data fall short of expectations.
Sector-level drivers include the rapid expansion of the U.S. cell-therapy market, projected to reach $45 billion by 2030, and favorable reimbursement trends for personalized immunotherapies. Yet, macro-level uncertainties-such as potential tightening of Medicare coverage for high-cost autologous products-remain a material risk factor for Iovance’s commercial outlook.
For a deeper quantitative comparison of IOVA’s risk-adjusted valuation, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -397.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.39 > 0.02 and ΔFCF/TA -1.13 > 1.0 |
| NWC/Revenue: 121.1% < 20% (prev 418.8%; Δ -297.7% < -1%) |
| CFO/TA -0.36 > 3% & CFO -323.1m > Net Income -397.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (364.0m) vs 12m ago 20.04% < -2% |
| Gross Margin: 38.76% > 18% (prev 0.09%; Δ 3867 % > 0.5%) |
| Asset Turnover: 26.42% > 50% (prev 9.17%; Δ 17.25% > 0%) |
| Interest Coverage Ratio: -30.12 > 6 (EBITDA TTM -368.3m / Interest Expense TTM -13.7m) |
Altman Z'' -15.00
| A: 0.34 (Total Current Assets 429.1m - Total Current Liabilities 125.8m) / Total Assets 904.9m |
| B: -2.99 (Retained Earnings -2.70b / Total Assets 904.9m) |
| C: -0.43 (EBIT TTM -412.0m / Avg Total Assets 948.0m) |
| D: -13.26 (Book Value of Equity -2.69b / Total Liabilities 202.7m) |
| Altman-Z'' Score: -24.39 = D |
Beneish M -2.99
| DSRI: 0.43 (Receivables 66.8m/55.8m, Revenue 250.4m/90.9m) |
| GMI: 0.23 (GM 38.76% / 8.85%) |
| AQI: 1.05 (AQ_t 0.33 / AQ_t-1 0.32) |
| SGI: 2.76 (Revenue 250.4m / 90.9m) |
| TATA: -0.08 (NI -397.6m - CFO -323.1m) / TA 904.9m) |
| Beneish M-Score: -2.99 (Cap -4..+1) = A |
What is the price of IOVA shares?
Over the past week, the price has changed by -3.07%, over one month by -3.07%, over three months by +6.75% and over the past year by -52.44%.
Is IOVA a buy, sell or hold?
- StrongBuy: 5
- Buy: 3
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the IOVA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.4 | 230% |
| Analysts Target Price | 8.4 | 230% |
| ValueRay Target Price | 2.1 | -17.8% |
IOVA Fundamental Data Overview February 03, 2026
P/B = 1.4414
Revenue TTM = 250.4m USD
EBIT TTM = -412.0m USD
EBITDA TTM = -368.3m USD
Long Term Debt = 1.00m USD (from longTermDebt, last fiscal year)
Short Term Debt = 7.28m USD (from shortTermDebt, last quarter)
Debt = 52.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -105.6m USD (from netDebt column, last quarter)
Enterprise Value = 764.0m USD (1.01b + Debt 52.5m - CCE 300.8m)
Interest Coverage Ratio = -30.12 (Ebit TTM -412.0m / Interest Expense TTM -13.7m)
EV/FCF = -2.17x (Enterprise Value 764.0m / FCF TTM -351.8m)
FCF Yield = -46.05% (FCF TTM -351.8m / Enterprise Value 764.0m)
FCF Margin = -140.5% (FCF TTM -351.8m / Revenue TTM 250.4m)
Net Margin = -158.8% (Net Income TTM -397.6m / Revenue TTM 250.4m)
Gross Margin = 38.76% ((Revenue TTM 250.4m - Cost of Revenue TTM 153.4m) / Revenue TTM)
Gross Margin QoQ = none% (prev 5.48%)
Tobins Q-Ratio = 0.84 (Enterprise Value 764.0m / Total Assets 904.9m)
Interest Expense / Debt = 6.64% (Interest Expense 3.49m / Debt 52.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -325.5m (EBIT -412.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.41 (Total Current Assets 429.1m / Total Current Liabilities 125.8m)
Debt / Equity = 0.07 (Debt 52.5m / totalStockholderEquity, last quarter 702.3m)
Debt / EBITDA = 0.29 (negative EBITDA) (Net Debt -105.6m / EBITDA -368.3m)
Debt / FCF = 0.30 (negative FCF - burning cash) (Net Debt -105.6m / FCF TTM -351.8m)
Total Stockholder Equity = 719.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -41.94% (Net Income -397.6m / Total Assets 904.9m)
RoE = -55.25% (Net Income TTM -397.6m / Total Stockholder Equity 719.8m)
RoCE = -57.16% (EBIT -412.0m / Capital Employed (Equity 719.8m + L.T.Debt 1.00m))
RoIC = -45.16% (negative operating profit) (NOPAT -325.5m / Invested Capital 720.8m)
WACC = 11.06% (E(1.01b)/V(1.06b) * Re(11.36%) + D(52.5m)/V(1.06b) * Rd(6.64%) * (1-Tc(0.21)))
Discount Rate = 11.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 19.26%
Fair Price DCF = unknown (Cash Flow -351.8m)
EPS Correlation: 93.73 | EPS CAGR: 73.21% | SUE: 0.37 | # QB: 0
Revenue Correlation: 88.29 | Revenue CAGR: 592.8% | SUE: -0.43 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.15 | Chg30d=+0.000 | Revisions Net=+3 | Analysts=6
EPS next Year (2026-12-31): EPS=-0.61 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+43.4% | Growth Revenue=+62.1%